Psoriatic Arthritis
News
Updated GRAPPA PsA recommendations call for integrated approach to care
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) includes comorbidities as a new clinical domain in its updated...
Commentary
Biologic treatment in pregnancy requires balancing risks
The effectiveness of immunoglobulin biologic treatments in controlling chronic and potentially debilitating autoimmune diseases means that more...
News
Secukinumab receives FDA approval for psoriatic arthritis, ankylosing spondylitis
Conference Coverage
EADV: Family history of cardiovascular disease is key in psoriasis patients
A family history of cardiovascular disease takes on extra importance in assessing cardiovascular risk in young adult psoriasis patients.
Conference Coverage
EADV: New oral psoriasis drug shows excellent safety
Key clinical point: The oral A3 adenosine receptor agonist CF1-1 shows promise as a potential first-line systemic therapy for moderate to severe...
Conference Coverage
ACR: Etanercept during pregnancy doubles the odds of major malformations
Key clinical point: Although etanercept exposure was associated with more than twofold higher odds of major structural defects, there was no...
News
Methotrexate has a role in treating articular manifestations of psoriatic arthritis
Patients with psoriatic arthritis taking methotrexate demonstrated an improvement in peripheral joint disease, skin disease, enthesitis,...
News
More comorbidity with PsA form of spondyloarthritis
Psoriatic arthritis (PsA) plus spondyloarthritis is associated with a significantly increased risk of cardiovascular and metabolic diseases,...
News
‘Cytokine converter’ cells alleviate psoriasis in mice
Implantation of cells designed to sense the presence of proinflammatory cytokines and subsequently produce and deliver anti-inflammatory molecules...
News
Poor response to third anti-TNF agent seen in most psoriatic arthritis patients
Key clinical point: Patients with psoriatic arthritis who don’t respond to or cannot tolerate two different anti-TNF agents are likely to respond...